FDA Warnings Slow, But Anti-Aging Claims Remain Class Action Targets
This article was originally published in The Rose Sheet
The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.
You may also be interested in...
Consumers with time on their hands at home have become better researched about plant-derived ingredients that deliver results, which, according to Lodaat Pharmaceuticals, is where cosmeceuticals are headed. Cosmeceutical possibilities and regulatory complexities were the substance of a panel discussion at CPhI Worldwide, featuring Lodaat director Rajiv Khatau and EAS Consulting’s John Bailey.
California federal courts have shown themselves receptive to proposed class actions alleging that purported cosmetics carrying unapproved drug claims violate the state’s Unfair Competition Law. Plaintiffs now are testing similar theories in suits against marketers of CBD-infused topical products.
The estimated $700,000 settlement puts to rest allegations that the luxury skin-care firm deceived consumers with claims about its PhytoCellTec ingredient’s ability to slow the aging process. G.M. Collin, another PhytoCellTec Malus Domestica user, also appears to have reached a deal with plaintiffs in litigation challenging its anti-aging claims.